75 Xarelto Suits Transferred to Philadelphia Mass Tort
Roughly 75 Xarelto lawsuits were transferred this week to newly-formed mass tort litigation in the Philadelphia Court of Common Pleas, court records indicate.
The decision was made public in an order docketed on January 21, in which a Pennsylvania judge ordered that the proceeding be created to centralize similar claims over the blood thinner. The cases similarly allege the failure of its manufacturers, Bayer HealthCare Pharmaceuticals and the Johnson & Johnson subsidiary, Janssen Pharmaceuticals, to warn about the severity of internal bleeding episodes that result from use of its product. While this complication is common to many medications, including the decades-old, warfarin, there is no antidote to stop Xarelto bleeding once it begins, which could make it uncontrollable and eventually increase a patient’s risk for death, claimants allege. Warfarin-related bleeding, in contrast, can be halted with the administration of Vitamin K.
Federal Xarelto MDL Now Underway in Louisiana
The creation of this Xarelto litigation comes at the heels of a similar one that is now underway in the U.S. District Court, Eastern District of Louisiana. On December 12, 2014, a federal panel agreed to transfer similar claims against Johnson & Johnson and Bayer at the request of numerous plaintiffs whose lawsuits allege serious episodes of gastrointestinal and cerebral hemorrhaging, deep vein thrombosis, pulmonary embolism, strokes and other complications.
Just a month after this litigation was established, a Case List updated in January showed 86 Xarelto lawsuit filings involving the anticoagulant, which belongs to a class known as direct thrombin inhibitors that also includes Boehringer Ingelheim’s Pradaxa. All of these products were cleared by the U.S. Food and Drug Administration (FDA) over the past few years to treat patients with atrial fibrillation: Xarelto in 2011 and Pradaxa in 2010. Since their market entrances, though, these products have been involved in thousands of complaint reports alleging serious harm.
In the first quarter of 2013 alone, an analysis from the Institute for Safe Medication Practices revealed 680 Xarelto side effect reports filed with the FDA. For the first time since its U.S. launch, the number of injury reports surpassed those involving Pradaxa.
Consider a Xarelto Lawsuit
Call an attorney at Bernstein Liebhard LLP to learn more about lawsuits that have already been filed over Xarelto, and find out whether you are eligible to file a claim against Bayer and Johnson & Johnson’s Janssen. Contact our Firm today at (877) 779-1414.